SEC Form 4 · accession 0001735276-18-000051
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yvonne Greenstreet
Officer — EVP, Chief Operating Officer
Period of report
Aug 13, 2018
Accepted (ET)
Aug 14, 2018 · 6:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 13, 2018 | A | 7,500 | $0.00 | A | 7,500 | D | |
| Common Stock | Aug 13, 2018 | F | 3,084 | $90.95 | D | 4,416 | D | |
| Common StockF2 | Apr 16, 2018 | J | 37 | $0.00 | A | 270 | I | by Managed Account |
| Common StockF2 | Jul 10, 2018 | J | 38 | $0.00 | A | 308 | I | by Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Stock Option 2016 (right to buy) | $77.10 | Aug 13, 2018 | A | 25,000 | A | Aug 13, 2018 | Sep 19, 2026 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1On June 29, 2017, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. One half of the shares subject to release will vest upon the achievement of each of two specific commercial events as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the first performance criterion has been met and one half of the shares have vested.
- F2Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F3On September 19, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. The shares subject to the option will vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the option shares have vested.